Ethicon Endo-Surgery has received Food and Drug Administration marketing clearance for a handheld version of its Mammotome minimally invasive breast-biopsy device. The new unit, called Mammotome Hand Held, will be available Sept. 20, according to the
Ethicon Endo-Surgery has received Food and Drug Administration marketing clearance for a handheld version of its Mammotome minimally invasive breast-biopsy device. The new unit, called Mammotome Hand Held, will be available Sept. 20, according to the Cincinnati-based division of Johnson & Johnson. Ethicon expects Mammotome Hand Held will be employed in physicians offices, breast care centers, and hospitals. Using ultrasound guidance, Mammotome Hand Held vacuums out suspicious tissue for examination, according to the company. The original table-mounted Mammotome has been available in the U.S. since 1995 and has been used for more than 375,000 breast biopsies.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.